Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David A. Hyman, MD, JD, on Inclusive Shared Savings

Jul

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

Deborah Collyar: What's In It for Patients?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David A. Hyman, MD, JD, on Inclusive Shared Savings

Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer

Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody

Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types

Avatrombopag Manages Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancer

Proton Pump Inhibitor, Antibiotic Exposure Linked to Worse Durvalumab Outcomes in Unresectable Stage III NSCLC